SEARCH

SEARCH BY CITATION

References

  • Amann K, Kronenberg G, Gehlen F, Wessels S, Orth S, Munter K, Ehmke H, Mall G & Ritz E (1998a). Cardiac remodelling in experimental renal failure—an immunohistochemical study. Nephrol Dial Transplant 13, 19581966.
  • Amann K, Rychlik I, Miltenberger-Milteny G & Ritz E (1998b). Left ventricular hypertrophy in renal failure. Kidney Int Suppl 68, S78S85.
  • Averill DB, Ishiyama Y, Chappell MC & Ferrario CM (2003). Cardiac angiotensin-(1–7) in ischemic cardiomyopathy. Circulation 108, 21412146.
  • Brilla CG, Zhou G, Matsubara L & Weber KT (1994). Collagen metabolism in cultured adult rat cardiac fibroblasts: response to angiotensin II and aldosterone. J Mol Cell Cardiol 26, 809820.
  • Burrell LM, Johnston CI, Tikellis C & Cooper ME (2004). ACE2, a new regulator of the renin-angiotensin system. Trends Endocrinol Metab 15, 166169.
  • Burrell LM, Risvanis J, Kubota E, Dean RG, MacDonald PS, Lu S, Tikellis C, Grant SL, Lew RA, Smith AI, Cooper ME & Johnston CI (2005). Myocardial infarction increases ACE2 expression in rat and humans. Eur Heart J 26, 369375; discussion 322–324.
  • Candido R, Forbes JM, Thomas MC, Thallas V, Dean RG, Burns WC, Tikellis C, Ritchie RH, Twigg SM, Cooper ME & Burrell LM (2003). A breaker of advanced glycation end products attenuates diabetes-induced myocardial structural changes. Circ Res 92, 785792.
  • Cao Z, Burrell LM, Tikkanen I, Bonnet F, Cooper ME & Gilbert RE (2001). Vasopeptidase inhibition attenuates the progression of renal injury in subtotal nephrectomized rats. Kidney Int 60, 715721.
  • Cao Z, Cooper ME, Wu LL, Cox AJ, Jandeleit-Dahm K, Kelly DJ & Gilbert RE (2000). Blockade of the renin-angiotensin and endothelin systems on progressive renal injury. Hypertension 36, 561568.
  • Crackower MA, Sarao R, Oudit GY, Yagil C, Kozieradzki I, Scanga SE, Oliveira-dos-Santos AJ, Da Costa J, Zhang L, Pei Y, Scholey J, Ferrario CM, Manoukian AS, Chappell MC, Backx PH, Yagil Y & Penninger JM (2002). Angiotensin-converting enzyme 2 is an essential regulator of heart function. Nature 417, 822828.
  • Dales NA, Gould AE, Brown JA, Calderwood EF, Guan B, Minor CA, Gavin JM, Hales P, Kaushik VK, Stewart M, Tummino PJ, Vickers CS, Ocain TD & Patane MA (2002). Substrate-based design of the first class of angiotensin-converting enzyme-related carboxypeptidase (ACE2) inhibitors. J Am Chem Soc 124, 1185211853.
  • Dean RG, Balding LC, Candido R, Burns WC, Cao Z, Twigg SM & Burrell LM (2005). Connective tissue growth factor and cardiac fibrosis after myocardial infarction. J Histochem Cytochem 53, 12451256.
  • Donoghue M, Hsieh F, Baronas E, Godbout K, Gosselin M, Stagliano N, Donovan M, Woolf B, Robison K, Jeyaseelan R, Breitbart RE & Acton S (2000). A novel angiotensin-converting enzyme-related carboxypeptidase (ACE2) converts angiotensin I to angiotensin 1–9. Circ Res 87, E1E9.
  • Duncan AM, Burrell LM, Kladis A & Campbell DJ (1996). Effects of angiotensin-converting enzyme inhibition on angiotensin and bradykinin peptides in rats with myocardial infarction. J Cardiovasc Pharmacol 28, 746754.
  • Eijkelkamp WB, Zhang Z, Brenner BM, Cooper ME, Devereux RB, Dahlof B, Ibsen H, Keane WF, Lindholm LH, Olsen MH, Parving HH, Remuzzi G, Shahinfar S, Snapinn SM, Wachtell K & De Zeeuw D (2007). Renal function and risk for cardiovascular events in type 2 diabetic patients with hypertension: the RENAAL and LIFE studies. J Hypertens 25, 871876.
  • Ferrario CM, Averill DB, Brosnihan KB, Chappell MC, Iskandar SS, Dean RH & Diz DI (2002). Vasopeptidase inhibition and Ang-(1–7) in the spontaneously hypertensive rat. Kidney Int 62, 13491357.
  • Ferrario CM, Jessup J, Chappell MC, Averill DB, Brosnihan KB, Tallant EA, Diz DI & Gallagher PE (2005). Effect of angiotensin-converting enzyme inhibition and angiotensin II receptor blockers on cardiac angiotensin-converting enzyme 2. Circulation 111, 26052610.
  • Foley RN, Parfrey PS, Harnett JD, Kent GM, Martin CJ, Murray DC & Barre PE (1995). Clinical and echocardiographic disease in patients starting end-stage renal disease therapy. Kidney Int 47, 186192.
  • Foley RN, Parfrey PS & Sarnak MJ (1998). Clinical epidemiology of cardiovascular disease in chronic renal disease. Am J Kidney Dis 32, S112S119.
  • Grobe JL, Mecca AP, Lingis M, Shenoy V, Bolton TA, Machado JM, Speth RC, Raizada MK & Katovich MJ (2007). Prevention of angiotensin II-induced cardiac remodeling by angiotensin-(1–7). Am J Physiol Heart Circ Physiol 292, H736H742.
  • Grobe JL, Mecca AP, Mao H & Katovich MJ (2006). Chronic angiotensin-(1–7) prevents cardiac fibrosis in DOCA-salt model of hypertension. Am J Physiol Heart Circ Physiol 290, H2417H2423.
  • Huentelman MJ, Grobe JL, Vazquez J, Stewart JM, Mecca AP, Katovich MJ, Ferrario CM & Raizada MK (2005). Protection from angiotensin II-induced cardiac hypertrophy and fibrosis by systemic lentiviral delivery of ACE2 in rats. Exp Physiol 90, 783790.
  • Iwata M, Cowling RT, Gurantz D, Moore C, Zhang S, Yuan JX & Greenberg BH (2005). Angiotensin-(1–7) binds to specific receptors on cardiac fibroblasts to initiate antifibrotic and antitrophic effects. Am J Physiol Heart Circ Physiol 289, H23562363.
  • Kawano H, Do YS, Kawano Y, Starnes V, Barr M, Law RE & Hsueh WA (2000). Angiotensin II has multiple profibrotic effects in human cardiac fibroblasts. Circulation 101, 11301137.
  • Kennedy D, Omran E, Periyasamy SM, Nadoor J, Priyadarshi A, Willey JC, Malhotra D, Xie Z & Shapiro JI (2003). Effect of chronic renal failure on cardiac contractile function, calcium cycling, and gene expression of proteins important for calcium homeostasis in the rat. J Am Soc Nephrol 14, 9097.
  • Lee AA, Dillmann WH, McCulloch AD & Villarreal FJ (1995). Angiotensin II stimulates the autocrine production of transforming growth factor-β1 in adult rat cardiac fibroblasts. J Mol Cell Cardiol 27, 23472357.
  • Liangos O, Wald R, O'Bell JW, Price L, Pereira BJ & Jaber BL (2006). Epidemiology and outcomes of acute renal failure in hospitalized patients: a national survey. Clin J Am Soc Nephrol 1, 4351.
  • Tikellis C, Johnston CI, Forbes JM, Burns WC, Burrell LM, Risvanis J & Cooper ME (2003). Characterization of renal angiotensin-converting enzyme 2 in diabetic nephropathy. Hypertension 41, 392397.
  • Tonelli M, Wiebe N, Culleton B, House A, Rabbat C, Fok M, McAlister F & Garg AX (2006). Chronic kidney disease and mortality risk: a systematic review. J Am Soc Nephrol 17, 20342047.
  • Tornig J, Amann K, Ritz E, Nichols C, Zeier M & Mall G (1996). Arteriolar wall thickening, capillary rarefaction and interstitial fibrosis in the heart of rats with renal failure: the effects of ramipril, nifedipine and moxonidine. J Am Soc Nephrol 7, 667675.
  • Vickers C, Hales P, Kaushik V, Dick L, Gavin J, Tang J, Godbout K, Parsons T, Baronas E, Hsieh F, Acton S, Patane M, Nichols A & Tummino P (2002). Hydrolysis of biological peptides by human angiotensin-converting enzyme-related carboxypeptidase. J Biol Chem 277, 1483814843.
  • Wilk S & Orlowski M (1983). Inhibition of rabbit brain prolyl endopeptidase by n-benzyloxycarbonyl-prolyl-prolinal, a transition state aldehyde inhibitor. J Neurochem 41, 6975.
  • Wu LL, Cox A, Roe CJ, Dziadek M, Cooper ME & Gilbert RE (1997). Transforming growth factor β1 and renal injury following subtotal nephrectomy in the rat: role of the renin-angiotensin system. Kidney Int 51, 15531567.
  • Yamamoto K, Ohishi M, Katsuya T, Ito N, Ikushima M, Kaibe M, Tatara Y, Shiota A, Sugano S, Takeda S, Rakugi H & Ogihara T (2006). Deletion of ACE2 accelerates pressure overload-induced cardiac dysfunction by increasing local angiotensin II. Hypertension 47, 110.
  • Zulli A, Burrell LM, Widdop RE, Black MJ, Buxton BF & Hare DL (2006). Immunolocalization of ACE2 and AT2 receptors in rabbit atherosclerotic plaques. J Histochem Cytochem 54, 147150.